Bonus Biogroup Ltd.
BBIXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$199.72M
Close$
$-0.00
110.5% downside
Current Fair Value
110.5% downsideOvervalued by 110.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $199.72 Million |
|---|---|
| Enterprise Value | $207.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | 0.84 |
| Outstanding Shares | 0 |
Return
| Return on Equity | 281.43% |
|---|---|
| Return on Assets | -168.59% |
| Return on Invested Capital | 1071.96% |
Valuation & Multiples
| P/E Ratio | -16.76 |
|---|---|
| PEG | 339.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.98 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.96 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bonus Biogroup Ltd.
42 employees
CEO: Shai Meretzki Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxil...